Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

NCT00654589 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
75
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals